ClinicalTrials.gg
RecruitingNCT06547827StrokeFit4Updated Jul 24, 2026

Rehabilitation With and Without Robot and Allied Digital Technologies in Stroke Patients

An interventional study of robotic rehabilitation and traditional rehabilitation in Stroke, sponsored by Fondazione Don Carlo Gnocchi ETS. Recruiting at 27 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Fondazione Don Carlo Gnocchi ETS · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
596
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 346 studies in Stroke with a site in Italy — 93 open to participants now, 106 under way, 3 of them phase 3. Stroke · Italy.

Planned enrollment
50th of 264
596 · median 76
Started
2024
with 17 others
No phase
208 of 346
66 open now
Primary completion
2026-11
later than 49 of 105 live
Registered
263rd of 346
by date
Lead sponsor
7 of 346
Fondazione Don Carlo Gnocchi ETS

Among the 346 studies in Stroke with a site in Italy, this one is the 50th largest by planned enrollment of the 264 interventional ones that give a count, is one of 18 that started in 2024, is one of 208 with no phase, reaches primary completion later than 49 of the 105 other live ones, and was the 263rd registered.

Stroke

8,281 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

93 of the 346 studies in Stroke with a site in Italy are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 346 studies in Stroke with a site in Italy, or all of them as a file.
02

Study summary

Rehabilitation after stroke often employs Robot and Allied Digital Technologies (RADTs), yet evidence on their effectiveness remains inconclusive due to study heterogeneity and limited sample sizes.

This multicentre randomized controlled pragmatic trial aims at comprehensively and accurately assessing the effectiveness of rehabilitation mediated by RADTs after a stroke, compared to traditional rehabilitation, also considering economic sustainability.

Read the detailed description

The aim of this study is to evaluate, in a pragmatic trial on a large sample of patients who have experienced a stroke within the six months prior to enrollment, the effectiveness of a multimodal treatment using robotics and advanced technologies compared to traditional multimodal treatment, in the recovery of activities of daily living.

Primary Objective: To demonstrate, in a population of subacute stroke patients, the non-inferiority of a rehabilitation treatment integrated with robotic and/or technological devices compared to traditional rehabilitative treatment in the recovery of activities of daily living.

Secondary Objectives:

  • To demonstrate the superiority of rehabilitative treatment integrated with robotic and/or technological devices compared to traditional rehabilitation treatment in the recovery of activities of daily living, should non-inferiority be demonstrated;
  • To compare the improvements between two groups in all targeted domains (upper limb sensorimotor abilities; lower limb sensorimotor abilities and gait; balance; cognitive abilities), in accordance with the International Classification of Functioning, Disability, and Health (ICF);
  • To analyze the neurophysiological parameters and factors involved in neuroplasticity processes;
  • To compare the time pattern of manual dexterity and walking performance recovery in the two groups;
  • To assess the effects of the rehabilitation treatment in terms of daily life activities and quality of life through medium-term follow-up;
  • To evaluate the acceptability and usability of the rehabilitative treatment integrated with robotic and/or technological devices for the patient, their family, and the healthcare practitioner;
  • To create a predictive model capable of forecasting the effectiveness of robotic and technological treatment in subjects after a stroke, based on a detailed description of the patient at baseline (using demographic data and clinical picture at admission);
  • To assess the economic sustainability of the rehabilitative treatment integrated with robotic and/or technological devices for the patient, payer, and society, through the creation of a model for the assessment and prediction of cost-effectiveness, cost-utility, and, for the healthcare system, a Budget Impact Analysis, and related sensitivity analyses.

The study employs a multicenter, multimodal, randomized, controlled, parallel-group (1:1) interventional design with blinded assessors, following a pragmatic approach. It will be conducted across multiple clinical centers involved in a national research initiative, encompassing both outpatient and inpatient settings. Randomization will be centralized and stratified by clinical center, latency, and clinical setting (inpatients or outpatients).

The sample size (596 patients) was determined considering the following, with respect to the primary outcome (the change in the modified Barthel Index): (a) the non-inferiority of robotic treatment compared to traditional treatment; (b) a power of 80%; (c) a non-inferiority margin of 5 points; (d) a bilateral 95% confidence interval; (e) a standard deviation of the primary outcome of 20 points. Considering these parameters, a sample size of 506 patients (253 per group) is obtained. Additionally, considering a dropout rate of 15%, a total sample size of 596 patients is obtained. The same sample size is sufficient to also demonstrate the potential superiority of robotic treatment. In fact, considering a significance level of 5%, a power of 80%, a minimal clinically important difference of the scale of 9.25 points, a standard deviation of 20 points, and a dropout rate of 15%, a total of 178 patients are required for demonstrating superiority.

The experimental group will receive rehabilitation using RADTs within a new organizational model, where two physical therapists supervise four to six patients. In the control group, patients will undergo individual traditional rehabilitation, maintaining a 1:1 patient-to-therapist ratio. In both groups, patients will undergo comprehensive rehabilitation treatment, targeting the following domains: a) upper limb sensorimotor abilities; b) lower limb sensorimotor abilities and gait; c) balance; d) cognitive abilities.

The primary outcome is to demonstrate non-inferiority in activities of daily living as measured by the modified Barthel Index. Should non-inferiority be established, the study will then evaluate the potential superiority of RADTs in activities of daily living.

All participating centers will follow a standardized operating procedure regarding treatment and outcome assessment to ensure consistency across all sites. Data will be systematically collected using the REDCap (Research Electronic Data Capture) platform.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • rehabilitation
  • robotics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First-ever diagnosis of ischemic or haemorrhagic stroke confirmed by Computed Tomography or Magnetic Resonance Imaging;
  • Age 18 years and over;
  • Time since the event equal to or less than 6 months;
  • Mild to severe impairment of the upper limb (motor section of the Fugl-Meyer Assessment of Upper Extremity ≤ 58) and/or mild to severe impairment of the lower limb (score on the Functional Ambulation Categories scale ≤ 4) and/or mild to severe impairment of balance (Berg Balance Scale ≤ 45);
  • Clinical stability allowing transfer to the gym and execution of the planned treatments.

Exclusion criteria

Exclusion Criteria:

  • Clinical instability;
  • Behavioral/cognitive disorders preventing adequate patient compliance with both traditional and robotic rehabilitation treatment (severe cognitive deficit, \<10);
  • Rigidity or hypertonia (Modified Ashworth Scale > 3) in the plegic/paretic limb;
  • Serious uncorrectable visual impairments preventing the patient from performing treatment with technological and/or robotic devices;
  • Pregnant women;
  • Refusal to sign the .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
596 participants (estimated)

Study arms

  • Experimental
    Integrated Treatment with Robotic & Technological Devices (RADTs)

    This intervention employs various RADTs to target the following domains: a) upper limb sensorimotor abilities; b) lower limb sensorimotor abilities and gait; c) balance; and d) cognitive abilities. For upper limb sensorimotor function, we will use planar end-effector robots, exoskeletons, or electromechanical systems for shoulder, elbow, and wrist rehabilitation; end-effector robots or exoskeletons for hand rehabilitation; and sensor-based devices for comprehensive upper limb treatment. For lower limb sensorimotor function, we will utilize end-effector robots or exoskeletons and treadmills with body-weight support systems. Balance training will involve stabilometric platforms and sensor-based systems. Cognitive functions will be addressed using digital systems, sensor-based devices, and virtual reality programs. All devices must have a CE mark for medical devices and be used according to the manufacturer's specifications.

    Other: robotic rehabilitation

  • Active comparator
    Traditional Treatment

    In the control group, subjects will undergo a standard traditional rehabilitation program without the use of RADTs, focusing on the following domains:a) upper limb sensorimotor abilities; b) lower limb sensorimotor abilities and gait; c) balance; and d) cognitive abilities, using traditional methods of physiotherapy and cognitive rehabilitation.

    Other: traditional rehabilitation

Interventions

  • Otherrobotic rehabilitation

    Treatment will occur in a gym equipped with devices for all the domains, with two physiotherapists supervising groups of 4 to 6 patients, depending on their clinical severity. Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency: * 5 times a week for 5 weeks, for inpatients; * 3 times a week for 8.3 weeks, for outpatients.

  • Othertraditional rehabilitation

    A physiotherapist-to-patient ratio of 1:1 is provided for the treatment in all participating centres. Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency: * 5 times a week for 5 weeks, for inpatients; * 3 times a week for 8.3 weeks, for outpatients.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the modified Barthel Index

    The modified Barthel Index for Activities of Daily Living is a validated ordinal scale which measures a person's ability to complete activities of daily living (ADL). Scores range from 0 (total dependence) to 100 (total independence).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

Secondary outcomes

  1. Fugl-Meyer Assessment for the upper extremities - motor function

    The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. The upper extremity motor function domain includes items assessing movement, coordination, and reflex action of the shoulder, elbow, forearm, wrist, and hand. It ranges from 0 (hemiplegia) to 66 (normal motor performance).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  2. Fugl-Meyer Assessment for the upper extremities - sensory function

    The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. The upper extremity sensory function domain evaluates light touch on two surfaces of the arm, and position sense for upper limb joints. It ranges from 0 to 12 (normal sensory function).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  3. Fugl-Meyer Assessment for the lower extremities - motor function

    The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. The lower extremity motor function domain includes items assessing movement, coordination, and reflex action of the hip, knee, and ankle. It ranges from 0 (hemiplegia) to 34 (normal motor performance).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  4. Fugl-Meyer Assessment for the lower extremities - sensory function

    The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. The lower extremity sensory function domain evaluates light touch on two surfaces of the leg, and position sense for lower limb joints. It ranges from 0 to 12 (normal sensory function).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  5. Berg Balance Scale

    The Berg Balance Scale (BBS) is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14-item scale designed to measure balance of the older adult in a clinical setting. It ranges from 0 to 56. A higher score indicates better balance.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  6. Symbol Digit Modalities Test

    The Symbol Digit Modalities Test evaluates information processing speed. It consists of a simple task of replacing symbols with numbers. Using a reference key, the patient has 90 seconds to match a sequence of symbols with the correspondent numbers as rapidly as possible. Both written or oral administration can be used. For each correct answer, a point is assigned. The higher the score, the faster the information processing speed.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  7. Modified Ashworth Scale

    The Modified Ashworth Scale (MAS) is a revised version of the original Ashworth Scale that measures spasticity in patients with lesions to the central nervous system. MAS is an assessment that is used to measure the increase in muscle tone. MAS assigns a grade of spasticity from a 0 to 4 ordinal scale. The grade is assigned by moving a joint/muscle through a high velocity quick stretch. The lower the score, the lower the spasticity. Upper and lower joints spasticity is assessed.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  8. Motricity Index for upper extremities

    The Motricity Index (MI) is an ordinal method of measuring limb strength. For upper extremity test, shoulder abduction, elbow flexion, pinch grip are considered. It ranges from 0 (worse) to 100 (normal strength).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  9. Motricity Index for lower extremities

    The Motricity Index (MI) is an ordinal method of measuring limb strength. For lower extremity test, hip flexion, knee extension, and ankle dorsiflexion are considered. It ranges from 0 (worse) to 100 (normal strength).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  10. Trunk control test

    The Trunk control test (TCT) measures four simple aspects of trunk movement. Total score range from 0 (minimum) to 100 (maximum, indicating better performance).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  11. Numerical Rating Scale for Pain

    The Numerical Rating Scale fo Pain (NRSP) is a subjective measure in which individuals rate their pain on an eleven-point numerical scale, from 0 (no pain) to 10 (worst pain imaginable).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  12. Neuropathic Pain 4 Questions

    The Neuropathic Pain 4 Questions (DN4) is a validated clinician-administered screening tool for neuropathic pain. It ranges from 0 to 10; higher values means higher neuropathic pain probability.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  13. Action Research Arm test

    The Action Research Arm Test (ARAT) is a 19 item observational measure used to assess upper extremity performance (coordination, dexterity and functioning). The 19 items comprising the ARAT are scored using a 4 point ordinal scale. Scores on the ARAT may range from 0-57 points, with a maximum score of 57 points indicating better performance.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  14. 2 Minute Walk Test

    The 2 Minute Walk Test (2MWT) is a measure of self-paced walking ability and functional capacity. The person is encouraged to walk as fast as they can, safely, without assistance for two minutes and the distance is measured.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  15. 5-level EQ-5D

    The 5-level EQ-5D (EQ-5D-5L) is a validated tool to assess health-related quality of life. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Index scores range from -0.59 to 1; 1 is the best possible health state. Negative values represent health states perceived as worse than dead, which is equal to 0.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  16. Brain Symmetry Index

    The Brain Symmetry Index (BSI) is a quantitative electroencephalographic (qEEG) measure used to assess the degree of symmetry in brain activity between the two hemispheres. It is defined as the mean absolute difference in spectral power of the EEG signals from homologous channels pairs on the left and right hemispheres, in the frequency range from 1 to 25 Hz. A higher BSI value indicates greater asymmetry, which is often associated with poorer clinical outcomes in stroke patients.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  17. Delta/Alpha Ratio

    The Delta/Alpha Ratio (DAR) is a quantitative electroencephalographic (qEEG) measure used to assess the balance between slow-wave (delta) and fast-wave (alpha) brain activity. It is calculated by dividing the power of delta waves (0.5-4 Hz) by the power of alpha waves (8-12 Hz). The DAR is particularly useful in evaluating brain function in stroke patients, as an increased DAR is often associated with greater brain dysfunction and poorer clinical outcomes.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  18. Change in serum concentration of Glial Fibrillary Acidic Protein (GFAP)

    Serum GFAP Concentration will be evaluated by "Ella" automated Immunoassay System method.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  19. Serum concentration of Neurofilament light (NfL)

    Serum NfL Concentration will be evaluated by "Ella" automated Immunoassay System method.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  20. Serum concentration of Brain Derived Neurotrophic Factor (BDNF)

    Serum BDNF Concentration will be evaluated by "Ella" automated Immunoassay System method.

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  21. 10 Meter Walk Test

    The 10 Meter Walk Test is a performance measure used to assess walking or gait speed in meters per second over a distance of 10 meters

    Time frame: baseline; within 24 hours from: the 5th rehabilitation session; the 10th rehabilitation session; the 15th rehabilitation session; the 20th rehabilitation session; the 25th rehabilitation session

  22. Box and block test

    The Box and Block Test (BBT) measures unilateral gross manual dexterity. It is a quick, simple and inexpensive test. The individual is instructed to move as many blocks as possible, one at a time, from one compartment to the other of a test box with 150 blocks and a partition in the middle. The number of blocks transferred in 60 seconds is recorded. Both the affected and the not affected side are measured.

    Time frame: baseline; within 24 hours from: the 5th rehabilitation session; the 10th rehabilitation session; the 15th rehabilitation session; the 20th rehabilitation session; the 25th rehabilitation session

  23. modified Barthel Index (follow-up)

    The Barthel Index for Activities of Daily Living is a validated ordinal scale which measures a person's ability to complete activities of daily living (ADL). Scores range from 0 (total dependence) to 100 (total independence).

    Time frame: 1 month after the end of the treatment; 2 months after the end of the treatment; 3 months after the end of the treatment; 4 months after the end of the treatment; 5 months after the end of the treatment; 6 months after the end of the treatment;

  24. EQ-5D-5L (follow-up)

    The 5-level EQ-5D version (EQ-5D-5L) is a validated tool to assess health-related quality of life. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Index scores range from -0.59 to 1; 1 is the best possible health state. Negative values represent health states perceived as worse than dead, which is equal to 0.

    Time frame: 1 month after the end of the treatment; 2 months after the end of the treatment; 3 months after the end of the treatment; 4 months after the end of the treatment; 5 months after the end of the treatment; 6 months after the end of the treatment;

Other outcomes

  1. premorbid Modified Rankin Scale

    The pre-stroke Modified Rankin Score (mRS) is an estimated score used to assess the patient's pre-stroke level of function. It has a grade ranging from 0 (no symptoms) to 6 (dead).

    Time frame: At baseline

  2. Life Time Physical Activity Questionnaire

    The Life Time Physical Activity Questionnaire (LTPAQ) is an interviewer-administered questionnaire used to estimate a respondent's physical activity done from childhood to the present.

    Time frame: At baseline

  3. Cognitive Reserve Index

    The Cognitive Reserve Index questionnaire (CRIq) aims to collect and estimate the amount of cognitive reserve acquired during a person's lifetime. In a single index (CRI), the questionnaire conveys three main sources of cognitive reserve: education, working activity, and leisure time activities. The CRIq score fell into 1 of 5 ordered levels: low (less than 70); medium-low (70-84); medium (85-114); medium-high (115-130); and high (more than 130).

    Time frame: At baseline

  4. National Institutes of Health Stroke Scale (NIHSS)

    It is validated tool for assessing stroke severity. NIHSS scores range from 0 to 42, with higher scores indicating more severe neurological deficit.

    Time frame: At baseline

  5. Cumulative Illness Rating Scale - severity index

    The Cumulative Illness Rating Scale (CIRS) is a well-validated multidimensional test commonly used as part of the Comprehensive Geriatric Assessment. It offers a comprehensive disease assessment for 14 organ systems, based on a rating scale ranging from 0 (best) to 4 (worst) for each. The severity index (CIRS-SI) is the mean of the scores of the first 13 categories (excluding the category of psychiatric/behavioral pathologies), ranging then from 0 to 4.

    Time frame: At baseline

  6. Cumulative Illness Rating Scale - comorbidity index

    The Cumulative Illness Rating Scale (CIRS) is a well-validated multidimensional test commonly used as part of the Comprehensive Geriatric Assessment. It offers a comprehensive disease assessment for 14 organ systems, based on a rating scale ranging from 0 (best) to 4 (worst) for each. The comorbidity index (CIRS-CI) is the number of categories in which a score greater than or equal to 3 is obtained (excluding the category of psychiatric/behavioral pathologies). This index ranges from 0 to 13, with 0 indicating no significant comorbidity and 13 indicating severe comorbidity in all categories.

    Time frame: At baseline

  7. Thumb Localizing Test

    It is a standardised measure of proprioception. It ranges from 0 (normal) to 3.

    Time frame: At baseline

  8. Semmes Weinstein filament test

    It measure the level of light touch sensation of the tips of the thumb and index finger. The Semmes Weinstein filament test kit consists of 20 flexible nylon monofilaments of constant length, but varying in diameter. They are labeled so as to give a linear scale of perceived intensity (1.65-6.65) using a logarithmic scale of applied force: labeled number = Log10 of (10 × force in milligrams). The more the labeled number increases, the thicker the filament becomes, and the more pressure is necessary to bend the filament, meaning lower level of light touch sensation.

    Time frame: At baseline

  9. Fatigue Severity Scale

    The Fatigue Severity Scale(FSS) is a nine-item instrument designed to assess fatigue as a symptom of a variety of different chronic conditions and disorders. The scale addresses fatigue's effects on daily functioning, querying its relationship to motivation, physical activity, work, family, and social life, and asking respondents to rate the ease with which they are fatigued and the degree to which the symptom poses a problem for them. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score is 9 and maximum score possible is 63. Higher score indicate greater fatigue severity.

    Time frame: At baseline

  10. Blaylock Risk Assessment Screening Score

    It is a simple and easy to use instrument that explores some important risk factors, such as social support, functional status, number of active medical problems and number of drugs, to identify the risk of prolonged hospitalization and the need of discharge planning in individuals who are hospitalized. It comprises a 10-item scale that determines a score between 0 and 40: a result lower than 10 identifies patients which have few needs for discharge planning and a low demand for discharge planning resources.

    Time frame: At baseline

  11. Montreal Cognitive Scale

    The Montreal Cognitive Assessment (MoCA) is a widely used screening assessment for detecting cognitive impairment. It ranges from 0 (worst) to 30 (best).

    Time frame: At baseline

  12. Intrinsic Motivation Inventory

    The Intrinsic Motivation Inventory (IMI) is a questionnaire that provides qualitative information on the content and level of motivation that an user experiences during an intervention Each IMI item consists of a seven-point Likert scale, ranging from "not at all true" to "completely true", with a maximum score of 144. Higher scores mean a more positive result on motivation.

    Time frame: within 24 hours from the 5th rehabilitation session

  13. Hospital Anxiety and Depression Scale

    It is a self-assessment scale for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic. The Hospital Anxiety and Depression Scale (HADS) is a 14-question instrument that measures anxiety and depression. Each question is scored between 0 (no impairment) and 3 (severe impairment), with a maximum score of 21 for anxiety or depression.

    Time frame: At baseline

  14. Beck Depression Inventory

    The Beck Depression Inventory (BDI-II), is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. The range of possible scores is 0 to 63. BDI-II scores are classified as minimal (0-13), mild (14-19), moderate (20-28), and severe (29-63) depression.

    Time frame: At baseline

  15. Mini Nutritional Assessment Short-Form

    It is a validated questionnaire for nutritional assessment. The total score range from 0 to 14 points, with scores of 12 to 14 points indicating normal nutritional status, scores between 8 and 11 points identifying patients at risk of malnutrition, and scores \< 8 points diagnosing malnutrition.

    Time frame: At baseline

  16. SARC-F

    The SARC-F questionnaire is a screening tool to identify probable sarcopenic patients. The questionnaire screens patients for self-reported signs suggestive of sarcopenia, which include deficiencies in strength, walking, rising from a chair, climbing stairs, and experiencing falls. Each of the self-reported parameters receives a minimum and maximum score of 0 and 2, respectively, with the greatest maximum SARC-F score being 10.

    Time frame: At baseline

  17. Functional Oral Intake Scale

    It is a tool to assess functional oral intake of food and liquids in patients with oropharyngeal dysphagia.specifically, it is a 7-point ordinal scale describing the functional level of oral intake of food and liquids. Level 7 represents a full oral diet with no restrictions, levels 6-4 indicate a full oral diet with restrictions, levels 3-2 describe a mixed oral and tube intake, while level 1 represents a totally tube-dependent intake.

    Time frame: At baseline

  18. Handgrip test

    It is an instrumented measure of grip strength.

    Time frame: At baseline

  19. Number of patients with the Brain Derived Neurotrophic Factor (BDNF) genetic polymorphism rs6265 (Val66Met) classified by genotype: homozygous GG (Valine/Valine), heterozygous GA (Valine/Methionine), or homozygous AA (Methionine/Methionine).

    It is a genetic analysis of BDNF polymorphism rs6265; it is performed using the HpyCH4IV restriction enzyme on DNA extracted from whole blood and amplified with PCR reaction. The polymorphism rs6265 identifies homozygous Valine/Valine, heterozygous Valine/Methionine and homozygous Methionine/Methionine.

    Time frame: At baseline

  20. 5-level EQ-5D

    The 5-level EQ-5D (EQ-5D-5L) is a validated tool to assess health-related quality of life. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Index scores range from -0.59 to 1; 1 is the best possible health state. Negative values represent health states perceived as worse than dead, which is equal to 0.

    Time frame: baseline; within 24 hours from the 15th rehabilitation session; within 24 hours from the 25th rehabilitation session

  21. Computer skills questionnaire

    It is an ad-hoc questionnaire to assess computer skills.

    Time frame: At baseline

  22. Technology Acceptance Model

    It is a questionnaire used with the primary aim of identifying the determinants involved in the acceptance of Robotic and Allied Technology. The questionnaire consists of 4 sections (perceived usefulness, ease of use, compatibility, intention to use); each question includes a 7-point Likert scale, from 1 (worst) to 7 (best). The scoring is calculated for each section and is given by the average of the responses in that section, ranging from 1 (worst) to 7 (best).

    Time frame: within 24 hours from the 5th rehabilitation session; within 24 hours from the 15th rehabilitation session; within 24 hours from the 25th rehabilitation session

  23. Questionnaire for satisfaction

    This is an ad-hoc questionnaire designed to measure satisfaction with healthcare services. Each question uses a 5-point Likert scale, ranging from 1 (unsatisfied) to 5 (very satisfied).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  24. Questionnaire for perception of problems and solution complexity

    It is an ad-hoc questionnaire for perception of problems and solution complexity. Each question utilizes a 5-point Likert scale, ranging from 1 (low complexity) to 5 (very complex).

    Time frame: baseline; within 24 hours from the 25th rehabilitation session

  25. Questionnaire for costs

    Ad-hoc questionnaire to evaluate the costs (direct healthcare costs, direct non-healthcare costs, indirect costs ) incurred by the patient.

    Time frame: baseline; within 24 hours from the 15th rehabilitation session; within 24 hours from the 25th rehabilitation session

  26. Incremental cost-utility ratio

    The incremental cost-utility ratio (ICUR) will serve as the key metric of the Cost-utility analysis, and it is calculated as the ratio between differences in costs and differences in utility across the analysis groups. Cost-utility analysis will assess and compare the efficiency of alternative rehabilitation interventions by measuring health outcomes in terms of utility, a measure of general well-being or quality of life (subjective measures), relative to the costs incurred to achieve these outcomes. Utilities will be evaluated using standardized measures based on quality of life. Each health condition identified through generic health-related quality of life questionnaires (EQ-5D-DL) will be associated with available utility scores specific to Italy.

    Time frame: During the study,an average of 24 months

  27. Incremental cost-effectiveness ratio

    The incremental cost-effectiveness ratio (ICER) is calculated by dividing the difference in costs between the alternative rehabilitation models tested in the clinical study by the difference in clinical outcomes (physical units - objective measures). It will be used as the key metric of the cost-effectiveness analysis, that will compare the costs and clinical outcomes of the alternative rehabilitation models being studied. The ICER represents the additional cost incurred to achieve an incremental unit of effectiveness, that will be assessed considering primary and secondary outcomes.

    Time frame: During the study, an average of 24 months

  28. Financial impact (differences in direct health costs)

    From the perspective of the payer, the expected outcome of the budget impact analysis is the assessment of the financial impact (differences in direct health costs) over a 3-5 year period for the diffusion of a mix of robotic-based rehabilitations, compared to conventional rehabilitation or a robotic solution. The financial impact will be assessed by considering the direct health costs associated with the different rehabilitation regimes, varying projections of robotic market uptake, and the degrees of substitutability between the compared rehabilitation regimes.

    Time frame: During the study, an average of 24 months

07

Study locations

27 of 27 sites recruiting
  • Fondazione Don Carlo Gnocchi, Centro Gala
    Acerenza, Italy
    Recruiting
    • Rocco Santarsiero · Contact
  • IRCCS Istituti Clinici Scientifici Maugeri
    Bari, Italy
    Recruiting
    • Pietro Fiore · Contact
  • Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
    Bergamo, Italy
    Recruiting
    • Silvia Galeri · Contact
  • Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco"
    Catania, Italy
    Recruiting
    • Michele Vecchio · Contact
  • Università degli Studi Magna Graecia di Catanzaro (A.O.U. "Renato Dulbecco" Catanzaro)
    Catanzaro, Italy
    Recruiting
    • Antonio Ammendolia · Contact
  • Istituto S. Anna di Ezio Pugliese s.r.l.
    Crotone, Italy
    Recruiting
    • Maria Elena Pugliese · Contact
  • Università di Foggia (Azienda Ospedaliero-Universitaria "Policlinico Riuniti" - Foggia)
    Foggia, Italy
    Recruiting
    • Andrea Santamato · Contact
  • IRCCS Ospedale Policlinico San Martino,
    Genova, Italy
    Recruiting
    • Trompetto Carlo · Contact
  • IRCCS Centro Neurolesi "Bonino Pulejo"
    Messina, Italy
    Recruiting
    • Rocco Salvatore Calabrò · Contact
  • Fondazione Don Carlo Gnocchi, IRCCS Santa Maria Nascente
    Milan, Italy
    Recruiting
    • Jorge Navarro · Contact
  • IRCCS Istituti Clinici Scientifici Maugeri
    Milan, Italy
    Recruiting
    • Christian Lunetta · Contact
  • IRCCS Istituti Clinici Scientifici Maugeri
    Montescano, Italy
    Recruiting
    • Cira Fundarò · Contact
  • Università degli Studi di Padova (Azienda Ospedale Università di Padova)
    Padova, Italy
    Recruiting
    • Stefano Masiero · Contact
  • IRCCS Fondazione Mondino
    Pavia, Italy
    Recruiting
    • Roberto De Icco · Contact
  • IRCCS Istituti Clinici Scientifici Maugeri
    Pavia, Italy
    Recruiting
    • Antonio Nardone · Contact
  • Università di Pisa (A.O.U. Pisana)
    Pisa, Italy
    Recruiting
    • Carmelo Chisari · Contact
  • Fondazione Don Carlo Gnocchi, Centro Santa Maria della Provvidenza
    Roma, Italy
    Recruiting
  • IRCCS San Raffaele Roma s.r.l.
    Roma, Italy
    Recruiting
    • Sanaz Pournajaf · Contact
  • Università Humanitas University - Hunimed (IRCCS Istituto Clinico Humanitas - Humanitas Mirasole S.p.A.)
    Rozzano, Italy
    Recruiting
    • Alessio Baricich · Contact
  • Fondazione Don Carlo Gnocchi, Centro Santa Maria al Mare
    Salerno, Italy
    Recruiting
    • Domiziano Tarantino · Contact
  • Università degli Studi di Salerno (Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona)
    Salerno, Italy
    Recruiting
    • Alessia Bramanti (UNISA) Marianna Amboni (AOU Ruggi) · Contact
  • Fondazione Don Carlo Gnocchi, Polo Specialistico Riabilitativo
    Sant'Angelo dei Lombardi, Italy
    Recruiting
    • Tommaso Cibellis · Contact
  • Azienda Sanitaria dell'Alto Adige - Ospedale di Vipiteno
    Sterzing, Italy
    Recruiting
    • Luca Sebastianelli · Contact
  • IRCCS Istituti Clinici Scientifici Maugeri
    Telese Terme, Italy
    Recruiting
    • Laura Marcuccio · Contact
  • APSS Trento
    Trento, Italy
    Recruiting
    • Jacopo Bonavita · Contact
  • Fondazione Don Carlo Gnocchi, Polo specialistico riabilitativo
    Tricarico, Italy
    Recruiting
    • Massimo Tolve · Contact
  • San Camillo IRCCS s.r.l.
    Venezia, Italy
    Recruiting
    • Pawel Kiper · Contact
08

References and documents

Publications

  • Aprile IG, Germanotta M, Fasano A, Siotto M, Mauro MC, Pavan A, Nicora G, Sgandurra G, Malovini A, Oreni L, Dubbini N, Parimbelli E, Comande G, Lunetta C, Fiore P, De Icco R, Trompetto C, Trieste L, Turchetti G, Quaglini S, Messa C; STROKEFIT4 Study Group. Rehabilitation with and Without Robot and Allied Digital Technologies (RADTs) in Stroke Patients: A Study Protocol for a Multicentre Randomised Controlled Trial on the Effectiveness, Acceptability, Usability, and Economic-Organisational Sustainability of RADTs from Subacute to Chronic Phase (STROKEFIT4). J Clin Med. 2025 Apr 15;14(8):2692. doi: 10.3390/jcm14082692. PubMed 40283522 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in the publication will be shared.

Supporting information: Study protocol

Time frame: Beginning six months after the publication, with no end date.

Access criteria: Access will be provided to the general scientific community and any interested researchers, for any type of analysis or secondary research use. The data will be made available on a public data-sharing platform such as Zenodo, or Figshare.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Nov 2026, 27 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 27 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 9, 2024
StartActual
Aug 12, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 30, 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06547827
Lead sponsor
Fondazione Don Carlo Gnocchi ETS
Collaborators
Istituti Clinici Scientifici Maugeri SpA, IRCCS National Neurological Institute "C. Mondino" Foundation, Ospedale Policlinico San Martino, Università di Pavia, Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Aug 12, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Jul 24, 2026

Study contacts

Irene G Aprile, MD, PhD
Contact
iaprile@dongnocchi.it
+390633086553
Marco Germanotta, PhD
Contact
mgermanotta@dongnocchi.it
+390633086553
Irene G Aprile
study director · IRCCS Fondazione Don Carlo Gnocchi
Irene G Aprile
principal investigator · IRCCS Fondazione Don Carlo Gnocchi
Christian Lunetta
principal investigator · IRCCS Istituti Clinici Scientifici Maugeri
Roberto De Icco
principal investigator · IRCCS Fondazione Mondino
Carlo Trompetto
principal investigator · IRCCS Ospedale Policlinico San Martino
Silvana Quaglini
principal investigator · Università di Pavia
Giuseppe Turchetti
principal investigator · Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion